Genmab Shares Surge 13.8 Percent on Copenhagen Stock Exchange
Genmab shares climbed 13.8 percent to 3,008.5 Danish crowns on the Copenhagen Stock Exchange, reaching a three-and-a-half-year high and topping the Stoxx Europe 600 index, borsaitaliana.it reported. The Danish pharmaceutical company advanced 48 percent from the beginning of the year through October 26, 2026.
The market movement follows positive follow-up data for the oncology treatment petosemtamab and an analyst upgrade from JP Morgan. Genmab presented the updated phase 2 trial results at the European Society for Medical Oncology congress in Madrid.
Phase 2 Petosemtamab Data in Metastatic Colorectal Cancer
Petosemtamab demonstrated objective response rates of 75 percent in first-line treatment and 67 percent in second-line treatment for metastatic colorectal cancer, according to Genmab’s data analysis presented in Madrid. The findings reflect a median follow-up of 5.9 months for first-line patients and 7.1 months for second-line patients.
With longer follow-up periods, the company reported that the majority of initially unconfirmed objective responses were subsequently confirmed. These figures indicate both depth and duration of response in patients with advanced disease.
Clinical Outlook from the University Hospital of Navarra
“Despite progress in the treatment of metastatic colorectal cancer, the prognosis remains unfavorable for many patients once the disease has spread,” said Dr. Ruth Vera of the Medical Oncology Department at the University Hospital of Navarra and a trial researcher.
Vera added that the response rates observed in both lines of therapy, alongside data maturation, suggest that petosemtamab combined with chemotherapy could provide a new therapeutic approach. Genmab stated that these results support the ongoing global Phase 3 development program for the drug.
JP Morgan Upgrade and Revenue Projections
JP Morgan raised its rating on Genmab from neutral to overweight, pointing to the strength of the company’s drug portfolio. The financial institution projects mid-double-digit annual revenue growth for the firm.
Alongside the upgrade for Genmab, JP Morgan adjusted its peak annual sales forecast for Epkinly to $2.5 billion. The bank also revised its sales projections upward for Rina-S, an ovarian cancer treatment in development.
Frequently Asked Questions
What metastatic cancer types are being evaluated with petosemtamab?
The updated phase 2 data presented at the European Society for Medical Oncology congress specifically evaluated petosemtamab in metastatic colorectal cancer across first-line and second-line treatment settings.
What specific financial upgrades did JP Morgan announce for Genmab?
JP Morgan upgraded Genmab from neutral to overweight, increased its peak annual sales forecast for Epkinly to $2.5 billion, and revised sales projections upward for the ovarian cancer treatment Rina-S.
Where were the latest petosemtamab clinical findings made public?
The updated trial analysis was presented at the European Society for Medical Oncology congress held in Madrid.